Autoimmune Lebererkrankungen bei Kindern und Jugendlichen

Autoimmune Lebererkrankungen, deren genaue Ursache bis heute unklar ist, stellen den Kliniker vor diagnostische und therapeutische Herausforderungen. Eine zeitgerechte Diagnosestellung ist zur Verhinderung von vermeidbaren irreversiblen Schäden oder Folgeerkrankungen des hepatobiliären Systems erforderlich. Die oft lebenslange Therapie muss genau abgewogen werden, um unerwünschte iatrogene und pharmakologische Nebenwirkungen zu minimieren.

Schlüsselwörter

Autoimmunhepatitis - sklerosierende Cholangitis - Ikterus - Autoantikörper

• Literatur

• 1 Oettinger R, Brunnberg A, Gerner P. et al. Clinical features and biochemical data of Caucasian children at diagnosis of autoimmune hepatitis. J Autoimmun 2005; 24: 79-84
• 2 Jimenez-Rivera C, Ling SC, Ahmed N. et al. Incidence and characteristics of autoimmune hepatitis. Pediatrics 2015; 136: e1237-1248
• 3 Schramm C, Lohse AW. Autoimmune hepatitis on the rise. J Hepatol 2014; 60: 478-479
• 4 Kerkar N, Hadzic N, Davies ET. et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998; 351: 409-413
• 5 Liberal R, Longhi MS, Mieli-Vergani G, Vergani D. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 653-664
• 6 Bittencourt PL, Goldberg AC, Cancado EL. et al. Different HLA profiles confer susceptibility to autoimmune hepatitis type 1 and 2. Am J Gastroenterol 1998; 93: 1394-1395
• 7 Liberal R, Grant CR, Longhi MS. et al. Diagnostic criteria of autoimmune hepatitis. Autoimmun Rev 2014; 13: 435-440
• 8 Longhi MS, Ma Y, Mitry RR. et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 2005; 25: 63-71
• 9 Caprai S, Vajro P, Ventura A. et al. SIGENP Study Group for Autoimmune Liver Disorders in Celiac Disease. Autoimmune liver disease associated with celiac disease in childhood: a multicenter study. Clin Gastroenterol Hepatol 2008; 6: 803-806
• 10 Mieli-Vergani G, Vergani D, Baumann U. et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr 2018; 66: 345-360
• 11 Hartl J, Ehlken H, Sebode M. et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol 2018; 68: 754-763
• 12 Gregorio GV, Portmann B, Karani J. et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544-553
• 13 Mieli-Vergani G, Heller S, Jara P. et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2009; 49: 158-164
• 14 Tiniakos DG, Brain JG, Bury YA. Role of Histopathology in Autoimmune Hepatitis. Dig Dis 2015; 33 Suppl 2: 53-64
• 15 Alvarez F, Berg PA, Bianchi FB. et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938
• 16 Hennes EM, Zeniya M, Czaja AJ et al., International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176
• 17 Ebbeson RL, Schreiber RA. Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful?. Clin Gastroenterol Hepatol 2004; 2: 935-940
• 18 Ferri PM, Ferreira AR, Miranda DM, Simoes E Silva AC. Diagnostic criteria for autoimmune hepatitis in children: a challenge for pediatric hepatologists. World J Gastroenterol 2012; 18: 4470-4473
• 19 Mileti E, Rosenthal P, Peters MG. Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children. Clin Gastroenterol Hepatol 2012; 10: 417-421.e1–e2
• 20 Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-185
• 21 Kerkar N, Annunziato RA, Foley L. et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr 2006; 43: 629-634
• 22 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. World J Gastroenterol 2017; 23: 6030-6048
• 23 Zizzo AN, Valentino PL, Shah PS, Kamath BM. Second-line agents in pediatric patients with autoimmune hepatitis: a systematic review and meta-analysis. J Pediatr Gastroenterol Nutr 2017; 65: 6-15
• 24 Duclos-Vallee JC, Sebagh M, Rifai K. et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003; 52: 893-897
• 25 Sokollik C, McLin VA, Vergani D. et al. Juvenile autoimmune hepatitis: A comprehensive review. J Autoimmun 2018; 95: 69-76
• 26 Di Giorgio A, DʼAdda A, Marseglia A. et al. Biliary features in liver histology of children with autoimmune liver disease. Hepatol Int 2019; 13: 510-518
• 27 Gregorio GV, Portmann B, Reid F. et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541-547
• 28 Rojas CP, Bodicharla R, Campuzano-Zuluaga G. et al. Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents. Fetal Pediatr Pathol 2014; 33: 202-209
• 29 Lindor KD, Kowdley KV, Luketic VA. et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814
• 30 Rodrigues AT, Liu PM, Fagundes ED. et al. Clinical characteristics and prognosis in children and adolescents with autoimmune hepatitis and overlap syndrome. J Pediatr Gastroenterol Nutr 2016; 63: 76-81
• 31 Deneau M, Jensen MK, Holmen J. et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology 2013; 58: 1392-1400
• 32 Koukoulis G, Mieli-Vergani G, Portmann B. Infantile liver giant cells: immunohistological study of their proliferative state and possible mechanisms of formation. Pediatr Dev Pathol 1999; 2: 353-359
• 33 Bernard O, Hadchouel M, Scotto J. et al. Severe giant cell hepatitis with autoimmune hemolytic anemia in early childhood. J Pediatr 1981; 99: 704-711
• 34 Maggiore G, Sciveres M, Fabre M. et al. Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children. J Pediatr 2011; 159: 127-132 e121
• 35 Marsalli G, Nastasio S, Sciveres M. et al. Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: A multicenter study. Clin Res Hepatol Gastroenterol 2016; 40: 83-89
• 36 Whitington PF, Vos MB, Bass LM. et al. Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia. J Pediatr Gastroenterol Nutr 2014; 58: 74-80
• 37 Kim YH, Kim JW, Lee EJ. et al. Successful treatment of a Korean infant with giant cell hepatitis with autoimmune hemolytic anemia using rituximab. Pediatr Gastroenterol Hepatol Nutr 2020; 23: 180-187
• 38 Matarazzo L, Di Chio T, Nastasio S. et al. B-cell depletion induces prolonged remission in patients with giant cell hepatitis and autoimmune hemolytic anemia. Clin Res Hepatol Gastroenterol 2020; 44: 66-72